Navigation Links
SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line
Date:10/27/2011

ST. LOUIS, Oct. 27, 2011 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that its custom manufacturing and services business unit, SAFC® (www.safcglobal.com), is introducing a novel CHOZN® GS-/- Zinc Finger Nuclease (ZFN)-modified Chinese Hamster Ovary (CHO) cell line. Designed for use in the production of biopharmaceuticals, the new CHOZN GS-/- cell line is the first commercially available glutamine synthetase (GS) knockout CHO cell line proven to shorten bioproduction times in early development, enabling customers to enhance their speed-to-market and increase cost efficiency. For more information, visit www.safcglobal.com/chozn.

CHOZN GS-/- was developed using SAFC's proprietary CompoZr® ZFN technology, that inactivates the glutamine synthetase gene rendering the cells dependent on L-glutamine. Development timelines for biopharmaceuticals can be shortened, as the cells do not require MSX (or L-Methionine-D, L-sulfoximine) selection for production clone development. "Knocking out" the GS gene that produces this enzyme means the addition of this MSX inhibitor is no longer required for r-protein clone selection, providing enhanced supply chain security, decreasing development time for identification of producing clones, and enabling customers to file Investigational New Drug (IND) applications sooner. The parental cell line is cGMP banked using Animal Component Free (ACF), Chemically Defined (CD) media and has extensive viral testing, along with a traceable history.

"The CHOZN GS-/- CHO cell line provides a solid foundation for SAFC's continued cell line development program," says Bruce Lehr, SAFC Director of Cell Sciences and Development. "It is expected to reduce production timelines, enabling customers to take their molecules to the clinic faster. Furthermore, it sets the stage for future products and capabilities in the area of upstream biopharmaceutical process development."

This new line follows the July, 2011 release of the CHOZN DHFR-/- CHO line. For more information on CHOZN DHFR and other CHOZN cell lines, visit www.safcglobal.com/chozn.

For more information on SAFC's CompoZr ZFN offer, visit: www.safcglobal.com/zfnkits.

For more information on SAFC's Cell Design Studio (CDS) offer, visit: www.safcglobal.com/cces.

The foregoing release contains forward-looking statements that can be identified by terminology such as "expected', "should", "proven", "enabling" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. There can be no guarantee that the products described in this release will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About SAFC®: SAFC is the custom manufacturing and services business unit of Sigma-Aldrich Corporation. We are recognized as a top 10 global fine chemical supplier and trusted manufacturer of specialty chemicals and biologics for the life science and high technology industries. Utilizing global "Centers of Excellence" and dedicated manufacturing facilities, SAFC can often resolve development and manufacturing challenges and accelerate the production of custom materials. Our rich portfolio includes high-purity inorganic materials for high technology applications, cell culture products, services for biopharmaceutical manufacturing and biochemical production, and complex, multi-step organic synthesis of APIs and key intermediates. For more information about SAFC, visit www.safcglobal.com.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 8,300 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning web site at www.sigma-aldrich.com.

Sigma-Aldrich, CompoZr, SAFC and CHOZN are registered trademarks of Sigma-Aldrich Co. LLC.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. Dr. Dello Russo Introduces the New EYE-Q Lasik
3. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
4. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
5. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
6. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
7. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
8. Siemens Introduces New Standard of Care for Breast Ultrasound
9. Perceptive Informatics Introduces Medical Imaging Methodology to Accelerate Development Decisions About Alzheimers Treatments
10. Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus
11. VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that ... Bisaro as Impax,s President and Chief Executive Officer ... 27, 2017. Mr. Bisaro will succeed J. Kevin ... Chief Executive Officer since December of 2016. ... experience, Mr. Bisaro, 56, is an accomplished global business ...
(Date:3/27/2017)... , March 27, 2017 Invivotek, LLC, a ... in vivo pharmacology contract research organization (CRO), ... to its newly expanded preclinical research facility in ... provides a cleaner, renewable energy source to reduce costs ... Completion of the Genesis Solar Farm follows Invivotek,s recent ...
(Date:3/24/2017)... 24, 2017  Zymo Research Corp., also ... Robotics, Inc., who designs, manufactures and distributes ... that teams Zymo Research,s DNA methylation detection ... extraction products with Hamilton,s high-throughput automation platforms. ... for microbiomics and RNA isolation for use ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... , ... A study by the founder of the Buckingham Center for ... was recently published in the American Journal of Cosmetic Surgery. “The Effects of an ... study on the use of Electro Lube during the facelift procedure. The journal, a ...
(Date:3/27/2017)... ... ... The Case Management Society of America (CMSA) will install six new members ... has elected their upcoming President-Elect, Secretary, Treasurer and two Directors to serve on the ... position has also been added to the BOD, per an appointment made by CMSA ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... enables researchers to pursue the recent RNA methylation “gold rush” with their established ... of the newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Anaheim Hills office ... First National Capital has added 10 new sales professionals over the past 6 months ... by 15 additional new hires over the course of 2017. , “This new ...
(Date:3/27/2017)... RICHEY, Fla. (PRWEB) , ... March 27, 2017 ... ... drug overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 of ... Kevin McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax on ...
Breaking Medicine News(10 mins):